SIGN UP
LOG IN
MARKET
NVS
NVS
Novartis
NYSE
97.05
+0.08
+0.08%
After Hours: 97.05 0 0.00% 16:00 12/06 EST
OPEN
97.47
PREV CLOSE
96.97
HIGH
97.65
LOW
96.72
VOLUME
3.82M
TURNOVER
0
52 WEEK HIGH
105.61
52 WEEK LOW
75.68
MARKET CAP
199.48B
P/E (TTM)
26.12
1D
5D
1M
3M
1Y
5Y
Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024
Pfizer has experienced a total return loss of nearly -40% in 2023. Downshifts in demand for covid-19 vaccines and antiviral products. Pfizer's stock is now trading at a significantly lower valuation compared to peers. 2023 has been a year to forget for pfizer, but the company's long-term growth prospects are bright. A dilutive $43 billion deal for seagen, a tornado destroying its north carolina production plant and trouble with its weight-loss drug development plan.
Seeking Alpha · 1d ago
Blackstone said to explore sale of Anthos, developer of blood thinners
Blackstone started anthos therapeutics four years ago with the backing of novartis to develop new blood thinners. Anthos could be worth several billion dollars in a potential sale, reuters reports. Blackstone invested $250m in anthos in 2019, and is said to be considering sale.
Seeking Alpha · 2d ago
Aspen Global To Acquire The Entire Share Capital Of Its Subsidiary, Sandoz (China) Pharmaceutical Co. With Commercialization Rights And Related Intellectual Property For A Portfolio Of Established Products
Aspen has concluded two agreements with sandoz ag concerning the acquisition of sandoz's chinese business and the disposal of four anaesthetic products in europe. Sandoz will acquire the entire share capital of its subsidiary sandoz (china) pharmaceutical co. Ltd. And the commercialisation rights of four products.
Benzinga · 2d ago
Weekly Report: what happened at NVS last week (1127-1201)?
Weekly Report · 2d ago
VYMI: Ex-U.S. Stocks Boast Big Yields, Low Valuations
Vanguard international high dividend yield index fund etf shares offers low valuation and solid long-term growth trends. Vymi: ex-u.s. Stocks boast big yields, low valuations compared to the s&p 500. Vymi has a high dividend yield, low expense ratio, and impressive etf grade. The fund has a low 8.8x price-to-earnings ratio, but its technical situation is mixed.
Seeking Alpha · 3d ago
10 Buffett-Style Dividend Aristocrats Yielding As Much As 10%
These 10 high-yield aristocrats average a 5.3% dividend, a-credit rating, and offer 12.6% long-term return potential. These aristocrats have almost 3x the return potential of the s&p 500. Stocks are having their best november in 43 years; stocks are 13% historically overvalued. Find the buffett-style dividend aristocrats yielding as much as 10% in our master list.
Seeking Alpha · 4d ago
AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time
Abbvie has agreed to acquire immunogen in a $10.1 billion all-cash deal. Immunogen's drug elahere received accelerated approval for the treatment of ovarian cancer. The company's oncology operations have been struggling in recent years. If the drug proves to be successful, the acquisition could be lucrative.
Seeking Alpha · 4d ago
(NVS) - Analyzing Novartis's Short Interest
Novartis's short percent of float has risen 5.56% since its last report. The company has 3.84 million shares sold short, which is 0.19% of all regular shares. Short interest is the number of shares that have been sold short but not yet covered.
Benzinga · 5d ago
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Webull offers Novartis AG (ADR) stock information, including NYSE: NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.